hepat
b
viru
hbv
infect
caus
major
public
health
problem
worldwid
clinic
limit
current
antivir
drug
hbv
lamivudin
emerg
drugresist
viral
strain
prolong
antivir
therapi
cepharanthin
hydrochlorid
ch
natur
alkaloidderiv
compound
report
possess
potent
activ
variou
virus
present
studi
perform
evalu
vitro
activ
ch
clinic
wildtyp
lamivudineresist
hbv
isol
transient
transfect
cell
hbv
dna
extract
serum
sampl
collect
lamivudin
therapi
time
viral
breakthrough
amplifi
polymeras
chain
reaction
pcr
amplicon
clone
novel
express
vector
initi
intracellular
hbv
replic
cycl
cell
transfect
follow
transfect
clone
amplicon
cell
drug
suscept
assay
perform
level
viral
antigen
hbeag
determin
enzymelink
immunosorb
assay
elisa
quantit
realtim
pcr
qpcr
use
determin
amount
intracellular
hbv
dna
heat
stress
cognat
host
protein
requir
hbv
replic
also
analyz
revers
transcript
pcr
rtpcr
explor
possibl
antivir
mechan
ch
result
show
ch
inhibit
replic
hbeag
product
either
wildtyp
lamivudineresist
hbv
clinic
isol
dosedepend
manner
mrna
also
downregul
significantli
conclus
ch
activ
wildtyp
lamivudineresist
hbv
clinic
isol
activ
may
associ
inhibit
host
hepat
b
viru
hbv
infect
caus
major
public
health
problem
worldwid
past
two
decad
prognosi
chronic
hepat
b
significantli
improv
due
emerg
two
formul
interferon
five
oral
administ
nucleo
ide
analog
yuen
lai
howev
prolong
use
nucleo
ide
analog
frequent
result
emerg
drugresist
hbv
mutant
respons
therapeut
failur
progress
liver
diseas
hongthanakorn
et
al
report
patient
develop
viral
resist
year
lamivudin
therapi
yuen
et
al
signatur
mutat
map
conserv
tyrosinemethionineaspartateaspart
ymdd
motif
within
c
domain
revers
transcriptas
rt
frequent
associ
lamivudin
resist
allen
et
al
furthermor
often
associ
compensatori
mutat
b
domain
rt
partial
restor
replic
capac
ymdd
mutat
strain
delaney
et
al
enomoto
et
al
one
vitro
studi
demonstr
drug
suscept
decreas
lamivudineresist
hbv
mutant
select
lada
et
al
moreov
rapid
progress
acut
exacerb
hepat
usual
occur
emerg
lamivudin
resist
suzuki
et
al
thu
discoveri
develop
novel
antihbv
drug
innov
target
urgent
need
treatment
chronic
hepat
b
especi
rescu
therapi
drugresist
patient
natur
herb
offer
good
candid
special
antivir
characterist
wide
use
chronic
hepat
b
treatment
cui
et
al
cepharanthin
hydrochlorid
ch
compound
manufactur
salif
cepharanthin
natur
biscoclaurin
alkaloid
extract
stephania
cepharantha
hayata
ch
attract
increas
scientif
attent
recent
year
due
extent
biolog
activ
includ
antitumor
antivir
antiinflammatori
action
abil
promot
leukocyt
induc
apoptosi
revers
multidrug
resist
induc
longeuropean
journal
pharmacolog
term
chemotherapi
rogosnitzki
dank
regard
antivir
activ
ch
thu
far
sever
report
human
immunodefici
viru
hiv
baba
et
al
sever
acut
respiratori
syndrom
coronaviru
sarscov
zhang
et
al
herp
simplex
viru
hsv
liu
et
al
howev
vitro
antihbv
activ
ch
never
explor
recent
unpublish
observ
demonstr
ch
effici
inhibitor
wildtyp
hbv
stabl
hbvproduc
cell
line
present
studi
investig
antivir
activ
ch
wildtyp
lamivudineresist
hbv
clinic
isol
transient
transfect
cell
preliminari
mechan
action
base
theori
host
heat
stress
cognat
requir
hbv
replic
wang
et
al
explor
chronic
hbvinfect
chines
man
initi
receiv
oral
lamivudin
monotherapi
mg
per
day
patient
serum
hbv
dna
decreas
copiesml
copiesml
receiv
lamivudin
monotherapi
month
becam
undetect
addit
month
lamivudin
therapi
unfortun
patient
serum
hbv
dna
rebound
copiesml
total
month
lamivudin
monotherapi
continu
rise
initi
level
month
later
time
point
genotyp
analysi
direct
sequenc
entir
polymeras
rt
region
circul
hbv
perform
reveal
presenc
tripl
mutat
addit
lamivudin
resistanceconf
mutat
resist
hbv
strain
genotyp
b
patient
seroposit
hbsag
hbeag
serum
sampl
collect
lamivudin
therapi
viral
breakthrough
respect
drug
suscept
analysi
access
materi
approv
ethic
committe
zhengzhou
univers
henan
china
inform
consent
obtain
patient
fig
puriti
determin
high
perform
liquid
chromatographi
hplc
maintain
laboratori
lamivudin
provid
glaxosmithklin
co
ltd
suzhou
china
adefovir
use
posit
control
inhibit
lamivudineresist
hbv
strain
obtain
glaxosmithklin
co
ltd
tianjin
china
stock
solut
mm
ch
lamivudin
adefovir
dissolv
phosphat
buffer
salin
pb
dilut
cultur
medium
desir
work
concentr
use
human
hepatoma
cell
line
obtain
china
center
typic
cultur
collect
cctcc
wuhan
china
cell
cultur
humidifi
co
atmospher
dulbecco
modifi
eagl
medium
dmem
hyclon
usa
supplement
fetal
bovin
serum
gibco
usa
unitsml
penicillin
g
streptomycin
novel
plasmid
express
vector
construct
kindli
provid
william
delaney
huil
yang
gilead
scienc
plasmid
contain
bp
hbv
sequenc
well
conserv
among
variou
hbv
genotyp
two
sapi
site
allow
insert
sapitr
pcramplifi
hbv
genom
yang
et
al
cytotox
test
compound
cell
determin
xtt
assay
describ
guo
et
al
except
durat
drug
administr
day
compound
assay
four
replic
least
five
concentr
cytotox
concentr
compound
reduc
cell
viabil
cc
determin
hbv
dna
extract
serum
sampl
use
commerci
viral
dna
extract
kit
omega
usa
fulllength
hbv
genom
amplifi
polymeras
chain
reaction
pcr
use
primer
thermocycl
condit
describ
et
al
pcr
product
digest
sapi
mbi
usa
ligat
sapidigest
shrimp
alkalin
phosphatasetr
plasmid
produc
recombin
clone
term
recombin
clone
serv
templat
sequenc
conserv
hbv
polymeras
rt
region
result
indic
clone
hbv
genom
directli
isol
serum
lamivudineresist
patient
harbor
tripl
mutat
expect
clone
hbv
genom
serum
collect
lamivudin
therapi
contain
mutat
use
wildtyp
control
select
recombin
clone
contain
wildtyp
mutat
hbv
genom
transient
transfect
cell
follow
briefli
sixwel
cultur
plate
corn
usa
seed
cellswel
h
earlier
transfect
dna
use
lipofectamin
invitrogen
usa
accord
manufactur
protocol
determin
effect
compound
cell
viabil
drug
treatment
initi
next
day
last
day
replac
fresh
drugfre
drugcontain
media
everi
day
concentr
ch
lamivudin
adefovir
use
drug
suscept
assay
day
drug
treatment
cell
cultur
supernat
cell
collect
store
subsequ
experi
day
drug
treatment
hbsag
hbeag
cell
cultur
supernat
detect
use
commerci
avail
elisa
kit
kehua
bioengin
corpor
shanghai
china
accord
manufactur
protocol
inhibit
rate
calcul
use
follow
formula
control
well
without
drug
experiment
well
control
well
without
drug
blank
control
well
without
cell
inhibitori
concentr
ic
calcul
regress
analys
quantiti
intracellular
hbv
dna
determin
quantit
realtim
pcr
base
taqman
technolog
brief
cell
rins
twice
cold
pb
lyse
lysi
buffer
contain
mm
trishcl
ph
mml
nacl
volvol
nonidet
centrifug
rpm
min
supernat
transfer
fresh
microcentrifug
tube
mgcl
ad
give
final
mg
concentr
mm
contamin
input
plasmid
digest
h
u
dnase
reaction
termin
mm
edta
hbv
dna
purifi
use
commerci
avail
viral
dna
extract
kit
omega
usa
quantit
realtim
pcr
perform
lightcycl
roch
germani
hbv
fluoresc
quantit
pcr
detect
kit
pg
biotech
shenzhen
china
accord
manufactur
instruct
initi
denatur
cycl
denatur
annealingextens
conduct
inhibitori
rate
ic
calcul
describ
elucid
antivir
mechan
ch
amount
host
mrna
determin
rtpcr
brief
exposur
differ
concentr
ch
day
total
rna
extract
collect
cell
sampl
trizol
reagent
invitrogen
usa
digest
rnasefre
dnase
promega
usa
min
follow
rtpcr
analysi
sequenc
primer
intern
refer
gapdh
gene
segment
amplifi
primer
gapdhf
gapdhr
rtpcr
program
min
min
follow
cycl
pcr
band
analyz
quantiti
one
softwar
biorad
usa
amount
genespecif
pcr
product
express
ratio
intens
band
correspond
gapdh
intern
refer
statist
analysi
perform
use
spss
softwar
spss
inc
chicago
il
usa
data
express
mean
sd
student
ttest
oneway
anova
use
determin
statist
signific
differ
group
valu
p
b
consid
statist
signific
cell
viabil
cell
evalu
xtt
assay
exposur
vari
concentr
compound
day
result
show
signific
cytotox
observ
lamivudin
highest
drug
concentr
wherea
cc
valu
adefovir
ch
respect
assess
inhibitori
efficaci
antivir
hbv
antigen
product
hbsag
hbeag
cultur
medium
detect
elisa
day
continu
exposur
increas
concentr
antivir
howev
level
hbsag
cell
transfect
tripl
mutant
low
data
shown
even
drugfre
group
exclud
antigen
criterion
antigen
inhibitori
effici
antivir
assess
base
hbeag
shown
fig
ch
lamivudin
adefovir
dosedepend
inhibit
hbeag
product
wildtyp
hbv
transfect
cell
ic
inhibit
hbeag
product
ch
howev
neither
lamivudin
adefovir
achiev
inhibit
hbeag
product
even
concentr
inhibitori
effici
ch
lamivudin
adefovir
hbeag
product
lamivudineresist
hbv
mutant
also
determin
expect
lamivudin
activ
lamivudineresist
hbv
mutant
wildtyp
hbv
howev
ch
caus
similar
inhibit
hbeag
product
lamivudineresist
hbv
fig
indic
ch
equal
effect
inhibitor
hbeag
express
lamivudineresist
hbv
wildtyp
viru
day
treatment
adefovir
dosedepend
inhibit
hbeag
product
also
observ
noteworthi
adefovir
show
rel
weaker
inhibit
hbeag
product
compar
ch
evalu
inhibitori
potenc
antivir
hbv
replic
intracellular
hbv
dna
extract
submit
realtim
pcr
analysi
end
treatment
demonstr
fig
consist
inhibitori
effect
hbeag
product
ch
lamivudin
adefovir
inhibit
replic
wildtyp
hbv
dosedepend
manner
potent
inhibit
observ
fig
effect
antivir
hbeag
product
wildtyp
lamivudineresist
hbv
cell
transient
transfect
wildtyp
lamivudineresist
b
hbv
genom
twentyfour
hour
transfect
cell
treat
indic
concentr
lamivudin
lam
adefovir
adv
cepharanthin
hydrochlorid
ch
day
treatment
hbeag
detect
cell
cultur
supernat
use
specif
elisa
kit
experi
perform
triplic
data
present
sd
three
independ
experi
p
b
p
b
compar
drug
control
group
lamivudin
ic
follow
ch
ic
adefovir
ic
respect
lamivudineresist
hbv
mutant
lamivudin
activ
tripl
mutant
resist
factor
ic
compar
wildtyp
hbv
strain
howev
exposur
ch
adefovir
produc
dosedepend
inhibit
replic
mutant
hbv
fig
ic
respect
exposur
increas
concentr
ch
day
amount
intracellular
mrna
also
determin
rtpcr
shown
fig
comparison
drugfre
group
level
mrna
chtreat
cell
transfect
either
wildtyp
mutat
hbv
genom
decreas
dosedepend
manner
parallel
reduct
intracellular
hbv
dna
worth
note
exposur
concentr
ch
signific
differ
level
mrna
wildtyp
hbvtransfect
cell
lamivudineresist
hbvtransfect
cell
p
emerg
hbv
strain
resist
antivir
treatment
major
clinic
concern
expand
use
prolong
administr
lamivudin
tripl
mutant
act
compensatori
mutat
partial
restor
replic
capac
mutat
strain
select
frequent
becam
next
common
mutat
profil
associ
lamivudin
resist
westland
et
al
one
altern
would
delay
overcom
occurr
drugresist
mutant
switch
add
novel
drug
share
resist
profil
mani
natur
herb
relat
activ
compound
report
promis
distinct
potent
antihbv
activ
studi
base
vitro
cell
transfect
system
assess
antivir
activ
ch
natur
alkaloidderiv
compound
wildtyp
lamivudineresist
hbv
clinic
isol
preliminari
mechan
action
ch
also
explor
due
lack
proofread
function
hbv
polymeras
combin
high
level
viral
replic
infect
liver
cell
chronic
hepat
b
patient
estim
basepair
error
occur
daili
doo
liang
consequ
hbv
chronic
infect
patient
harbor
mani
viru
quasispeci
contain
divers
genet
context
present
vitro
drug
suscept
assess
hbv
mutant
commonli
depend
method
artifici
reproduc
one
resist
mutat
usual
sitedirect
mutagenesi
laboratori
strain
wildtyp
viru
backbon
jacquard
et
al
howev
virus
creat
sitedirect
mutagenesi
fig
inhibitori
effect
antivir
viral
replic
wildtyp
lamivudineresist
hbv
cell
transient
transfect
wildtyp
lamivudineresist
b
hbv
genom
twentyfour
hour
transfect
cultur
treat
indic
concentr
lamivudin
lam
adefovir
adv
cepharanthin
hydrochlorid
ch
day
treatment
viral
dna
extract
cultur
cell
quantifi
realtim
quantit
pcr
use
commerci
avail
kit
experi
perform
triplic
data
present
mean
sd
three
independ
experi
p
b
p
b
compar
drug
control
group
fig
effect
ch
host
mrna
cell
transient
transfect
wildtyp
lamivudineresist
hbv
genom
treat
cepharanthin
hydrochlorid
ch
concentr
day
end
treatment
total
rna
extract
heat
stress
cognat
mrna
determin
rtpcr
b
level
mrna
quantifi
normal
rel
intern
refer
gapdh
mrna
c
experi
perform
triplic
repres
set
data
present
p
b
p
b
compar
drug
control
group
laboratori
strain
would
contain
natur
genet
context
mutat
identifi
clinic
strain
discrep
suscept
antivir
laboratoryand
patientderiv
hbv
mutant
emerg
brunel
et
al
therefor
phenotyp
analysi
hbv
clinic
mutant
isol
directli
sera
patient
would
offer
relev
accur
inform
obtain
test
virus
mutat
introduc
laboratori
strain
report
previous
report
express
vector
clone
entir
hbv
genom
use
facilit
replic
gene
express
fulllength
clinic
hbv
isol
novel
plasmid
contain
bp
hbv
sequenc
highli
conserv
among
variou
hbv
genotyp
contain
two
sapi
site
allow
insert
sapi
treat
pcramplifi
hbv
genom
lead
length
hbv
genom
necessari
suffici
enabl
synthesi
fulllength
hbv
pregenom
rna
pgrna
requir
trigger
intracellular
hbv
cycl
seeger
mason
present
studi
fulllength
hbv
genom
amplifi
highfidel
pcr
polymeras
serum
chronic
hepat
b
patient
develop
resist
lamivudin
clone
use
drug
suscept
test
sequenc
individu
clone
match
respect
patient
serum
hbv
indic
construct
individu
clone
repres
domin
serum
hbv
quasispeci
popul
thu
drug
suscept
result
obtain
report
would
precis
reflect
serum
hbv
hbv
genom
polymeras
gene
overlap
surfac
antigen
gene
result
mutat
rt
domain
might
affect
product
hbsag
protein
introduc
stop
codon
open
read
frame
orf
pollicino
et
al
wakil
et
al
present
studi
transient
transfect
tripl
mutant
cell
secret
hbsag
extrem
low
level
even
drug
control
group
thu
hbsag
exclud
antigen
criterion
evalu
suscept
tripl
mutant
antivir
antigen
inhibitori
effici
antivir
assess
base
hbeag
product
recent
assess
vitro
potenc
ch
inhibit
wildtyp
hbv
stabli
express
hbv
cell
line
present
studi
confirm
find
previou
studi
show
ch
potent
inhibitor
wildtyp
hbv
vitro
cell
transient
transfect
wildtyp
hbv
genom
ch
inhibit
hbv
replic
hbeag
express
effici
adefovir
lamivudin
display
potent
antivir
activ
moreov
provid
new
inform
show
ch
inhibit
replic
hbeag
product
clinic
lamivudineresist
hbv
isol
almost
effici
wildtyp
hbv
vitro
crossresist
profil
ch
lamivudineresist
variant
studi
prove
favor
lamivudin
compar
adefovir
cours
vitro
therapeut
potenc
drug
depend
antivir
capac
cytotox
effect
also
taken
account
sinc
select
index
ic
cc
drug
may
prevent
use
optim
dose
reach
potent
antivir
effect
interestingli
cytotox
assay
indic
ch
adefovir
similar
cytotox
cell
thu
combin
antivir
capac
profil
compound
test
conclud
ch
favor
therapeut
potenc
adefovir
although
natur
herb
relat
activ
compound
use
chronic
hepat
b
treatment
mechan
action
compound
remain
unclear
recent
research
found
host
protein
associ
hbv
replic
could
therapeut
target
natur
antihbv
compound
wang
et
al
gain
new
insight
mechan
inhibit
hbv
ch
assess
effect
vitro
ch
treatment
host
mrna
rtpcr
result
show
ch
inhibit
host
mrna
express
parallel
inhibitori
effect
intracellular
hbv
replic
illustr
ch
may
suppress
hbv
via
downregul
host
express
also
investig
potenti
influenc
knockdown
mrna
host
cell
interestingli
reduct
mrna
ch
caus
appar
neg
effect
growth
human
cell
unpublish
observ
nevertheless
downregul
protein
exact
mechan
downregul
ch
deserv
studi
furthermor
effect
ch
atpbind
protein
heat
stress
protein
like
chaperon
protein
like
hop
involv
hbv
replic
also
merit
investig
conclus
find
indic
ch
potent
inhibitor
clinic
wildtyp
lamivudineresist
hbv
isol
deserv
investig
compound
may
new
altern
candid
treatment
chronic
hepat
b
patient
develop
resist
lamivudin
furthermor
ch
might
also
valuabl
combin
therapi
approv
nucleo
ide
analog
prevent
delay
emerg
drugresist
mutant
chronic
hbvinfect
patient
